Name | NEO2734 |
Synonyms | EP31670 NEO2734 |
CAS | 2081072-29-7 |
Molecular Formula | C22H24F3N3O3 |
Molar Mass | 435.44 |
Solubility | ( < 1 mg/ml refers to the product slightly soluble or insoluble) |
Storage Condition | -20℃ |
Use | NEO2734 (EP31670) is a selective inhibitor of p300/CBP and BET bromodomain with oral activity, and its IC50 value is <30 nM. NEO2734 is active in both SPOP mutant and wild-type prostate cancer models. |
Target | p300/CBP; BET bromodomain |
Reference Show more | 1. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer2. Chevaun D Morrison-Smit, et al. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Mol Cancer Ther. 2020 Jul;19(7):1406-1414. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 0 ml | 0 ml | 0 ml |
5 mM | 0 ml | 0 ml | 0 ml |
10 mM | 0 ml | 0 ml | 0 ml |
5 mM | 0 ml | 0 ml | 0 ml |
biological activity | NEO2734 (EP31670) is a new, orally Active selective dual inhibitors of p300/CBP and BET bromodomain both correspond to IC50 values <30 nM. |
Target | TargetValue p300/CBP (Cell-free assay) <30 nM BET (Cell-free assay) <30 nM |
Target | Value |
p300/CBP (Cell-free assay) | <30 nM |
BET (Cell-free assay) | <30 nM |